Kisspeptin
A naturally occurring neuropeptide that plays a central role in reproductive hormone regulation and fertility.
What is Kisspeptin?
Kisspeptin is a naturally occurring neuropeptide that acts as a master regulator of the reproductive hormone axis. It stimulates the release of GnRH (gonadotropin-releasing hormone), which in turn triggers the release of LH and FSH — the hormones that drive testosterone and estrogen production. Multiple randomized controlled trials have demonstrated its efficacy as an IVF oocyte maturation trigger, and clinical studies show it can modulate sexual desire via brain processing pathways.
What Kisspeptin Is Investigated For
Kisspeptin is investigated for reproductive hormone regulation, IVF oocyte maturation triggering, hypoactive sexual desire disorder, and puberty diagnostics — all anchored in its well-characterized role as the master regulator of the HPG axis upstream of GnRH. The strongest evidence is for kisspeptin-54 as an IVF oocyte maturation trigger: multiple RCTs from Waljit Dhillo's group at Imperial College show effective egg maturation with meaningfully reduced ovarian hyperstimulation syndrome risk compared to hCG. HSDD applications have RCT-level support in both men and women, showing enhanced sexual and emotional brain processing — though therapeutic translation is still early. Chronic dosing is limited by tachyphylaxis at the kisspeptin receptor, which makes kisspeptin mechanistically unsuitable as a 'TRT alternative' despite forum marketing in that direction. Kisspeptin is not FDA-approved for any indication — even the IVF application, where the clinical evidence is strongest, remains pre-regulatory in the US. Research-chemical kisspeptin-10 is distinct from the GMP-grade peptide used in trials and carries real purity and sequence-verification risks for a compound directly driving the reproductive axis.
History & Discovery
Kisspeptin was discovered in 1996 as a metastasis-suppressor gene (KISS1) in melanoma cells at Hershey Medical Center in Pennsylvania — and named in a nod to the town's Hershey's Kisses. The reproductive biology role emerged years later: in 2003, independent groups led by Stéphanie Seminara at Massachusetts General Hospital and Nicolas de Roux at INSERM in Paris showed that loss-of-function mutations in the kisspeptin receptor (KISS1R/GPR54) caused hypogonadotropic hypogonadism, establishing the peptide as the master regulator of the reproductive axis. Imperial College London's group under Waljit Dhillo has driven much of the modern human clinical work — establishing safety, optimizing dosing, and pioneering the use of kisspeptin-54 as an IVF trigger. Dhillo's group demonstrated efficacy in women with hypothalamic amenorrhea, showed kisspeptin modulates brain responses to sexual and emotional cues in humans, and most importantly developed kisspeptin-54 as an alternative to hCG for triggering final oocyte maturation in IVF — potentially eliminating the risk of severe ovarian hyperstimulation syndrome. Myovant's synthetic kisspeptin receptor agonist MVT-602 has entered Phase II clinical development. Despite this clinical traction, no kisspeptin product is currently FDA-approved.
How It Works
Kisspeptin acts as the master switch for your reproductive hormones. It tells the brain to release the signals that ultimately lead to testosterone and estrogen production. It sits at the very top of the hormonal cascade.
Kisspeptin binds to the GPR54 (KISS1R) receptor on GnRH neurons in the hypothalamus, stimulating GnRH pulse generation. This activates the HPG axis, increasing LH and FSH secretion from the anterior pituitary, which drives gonadal steroidogenesis. Kisspeptin neurons integrate metabolic, circadian, and stress signals to regulate reproductive function.
Evidence Snapshot
Human Clinical Evidence
Moderate-to-strong. Multiple RCTs demonstrate efficacy as an IVF oocyte maturation trigger with reduced OHSS risk. Clinical trials show effects on sexual desire in both men and women with HSDD. Intranasal delivery has been validated in RCTs. Systematic reviews and meta-analyses support diagnostic and therapeutic applications.
Animal / Preclinical
Strong. Kisspeptin biology is well characterized in reproductive endocrinology.
Mechanistic Rationale
Very strong. The kisspeptin-GnRH-gonadotropin axis is a fundamental endocrine pathway.
Research Gaps & Open Questions
What the current literature has not yet settled about Kisspeptin:
- 01Long-term safety of repeated kisspeptin dosing in humans — most clinical data covers single doses or 8-week courses; chronic effects beyond a few months are uncharacterized.
- 02Optimal dosing strategies to avoid tachyphylaxis — understanding pulsatile vs. continuous delivery for specific indications remains incomplete.
- 03Cancer risk — as a metastasis-suppressor gene in some tumor models but pro-proliferative in others, kisspeptin's net effect on cancer risk with repeated therapeutic administration is unclear.
- 04Pediatric applications — while kisspeptin is used diagnostically for puberty disorders, therapeutic pediatric use would require extensive safety work that has not been conducted.
- 05Effects on mood and behavior — Dhillo's brain-imaging studies suggest non-reproductive effects (sexual desire, emotional processing) but therapeutic implications are underexplored.
- 06Sex-specific dosing — male and female reproductive physiology differ fundamentally, and optimal dosing likely differs but has not been head-to-head compared in matched populations.
- 07MVT-602 and other synthetic receptor agonists — whether a small-molecule agonist will supersede the native peptide in drug development remains an open question.
Forms & Administration
Kisspeptin is administered via subcutaneous or intravenous injection in clinical trials. Intranasal delivery has shown rapid gonadotropin stimulation in RCTs. A kisspeptin receptor agonist (MVT-602) is in clinical development. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
In published clinical trials, kisspeptin-54 (the full-length human form) has been studied at IV doses from 0.4 to 6.4 nmol/kg for HPG axis stimulation, and at ~9.6 nmol/kg subcutaneously as an IVF oocyte maturation trigger. Kisspeptin-10 (the shorter C-terminal decapeptide) has been used in trials at 0.3 to 1.0 nmol/kg/hr IV infusions. Intranasal kisspeptin-54 has shown rapid gonadotropin stimulation at 3.2 nmol/kg. Research-chemical markets sell kisspeptin-10 at unvalidated doses (often 100–200 mcg SC) that do not correspond to any published clinical protocol.
Frequency
Single-dose IVF trigger is the most clinically validated application. For hypothalamic amenorrhea, trial protocols have used twice-weekly dosing over 8 weeks. Continuous infusion produces tachyphylaxis (receptor desensitization) within days, making chronic continuous dosing counterproductive.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Not a chronic-use peptide in any clinical setting. Even in the hypothalamic amenorrhea trials, the 8-week pulsed protocol was driven by research considerations, not sustained therapeutic use. The tachyphylaxis issue limits long-term strategies unless explicitly designed around pulsatile signaling.
Protocol Notes
Route matters significantly: IV produces sharp gonadotropin rises; SC is more practical and has been validated for the IVF trigger application; intranasal achieves rapid effect but has not been extensively characterized. The difference between kisspeptin-54 (full-length) and kisspeptin-10 (short form) is practical — both bind KISS1R but pharmacokinetics and convenient dosing differ. Research-chemical supply of kisspeptin-10 is common; supply quality (peptide purity, correct sequence, sterility) is unverifiable without certificate-of-analysis from reputable sources.
Kisspeptin is not FDA-approved for any therapeutic indication. The IVF trigger application is clinical-trial stage in the US, regulatory-approved in some European contexts. Any use should be under qualified fertility-clinic or endocrinologist supervision.
Timeline of Effects
Onset
LH and FSH rise within 15–30 minutes of IV bolus. Testosterone and estradiol responses follow over hours as the pituitary stimulates the gonads. For IVF trigger application, oocyte maturation occurs 36–38 hours post-injection — similar to hCG timeline.
Peak Effect
Peak gonadotropin response occurs within 1–2 hours for kisspeptin-54 IV. The sexual-desire brain-imaging effects studied by Dhillo's group appeared within hours of administration. For the chronic hypothalamic amenorrhea protocol, meaningful sustained hormonal response was seen over the 8-week course.
After Discontinuation
Because kisspeptin acts upstream of GnRH, effects resolve when circulating kisspeptin clears and endogenous regulation resumes — typically within hours. No HPG-axis suppression or rebound effect has been documented, distinguishing it from GnRH agonists (leuprolide, triptorelin) that cause prolonged downregulation. For chronic protocols, the concern is tachyphylaxis during use rather than withdrawal effects after.
Monitoring & Measurement
Bloodwork & Labs
- •LH and FSH — the core hypothalamic-pituitary response markers
- •Total and free testosterone (men) or cycle-timed estradiol and progesterone (women)
- •Estradiol via sensitive LC-MS/MS assay — standard immunoassays are unreliable at male physiologic ranges
- •SHBG — interprets free testosterone
- •Prolactin — rules out a confounding hyperprolactinemia
Functional & Performance Tests
- •Semen analysis — if the protocol goal is fertility restoration or preservation
- •Testicular volume via orchidometer (men)
- •Subjective libido, energy, and mood tracking
When to Test
Baseline, 4 weeks, and 12 weeks of a protocol. For acute response confirmation, draw LH at 30–60 minutes post-injection on the first dose.
Interpretation & Notes
Kisspeptin acts upstream of GnRH, so the most informative single test is an acute LH measurement 30–60 minutes after a dose — a rise above roughly 2x baseline confirms the hypothalamic-pituitary axis is responsive. Sustained protocols aim for LH, FSH, and sex steroids back within reference range; failure to move those markers at 12 weeks points to pituitary pathology rather than kisspeptin insufficiency. Clinical availability is limited as of 2026 — most use is research-context, which makes source verification and clinical supervision the dominant safety factors. Standard reproductive-hormone panels are direct-to-consumer; acute post-dose draws require a clinician order.
Common Questions
Who Kisspeptin Is NOT For
- •Pregnancy — kisspeptin rises physiologically during pregnancy and artificial administration carries unknown risks to gestation; no safety data exists for exogenous use during pregnancy.
- •Hormone-sensitive cancers (prostate, breast, ovarian, endometrial) — kisspeptin stimulates the HPG axis, which drives gonadal steroid production that can fuel hormone-sensitive tumor growth.
- •Known KISS1R or GPR54 mutations — these individuals have impaired kisspeptin signaling and may not respond predictably; the context for use would be medical specialist supervision only.
- •Ongoing fertility treatment with GnRH antagonists — the mechanisms can interact unpredictably; IVF trigger protocols using kisspeptin are distinct clinical pathways requiring specialist coordination.
- •Pediatric use — puberty-stage effects of exogenous kisspeptin are not well characterized; any pediatric use belongs in specialist endocrine contexts for precocious-puberty or delayed-puberty diagnostics only.
- •Research-chemical supply — given reproductive-axis effects, unverified-purity product introduces unacceptable risk of off-target contaminants triggering hormonal disruption.
Drug & Supplement Interactions
Kisspeptin's mechanism — driving endogenous LH and FSH pulses — interacts predictably but significantly with any medication that targets the HPG axis. GnRH agonists (leuprolide, triptorelin) and antagonists (cetrorelix, degarelix) used for prostate cancer, endometriosis, or IVF cycle control will have altered effects if kisspeptin is co-administered. Hormonal contraceptives suppress the HPG axis; kisspeptin's stimulation may partially overcome this suppression, with uncertain implications for contraceptive efficacy. Testosterone replacement therapy may blunt kisspeptin's downstream testosterone-raising effect due to negative feedback. Exogenous estrogens or progestins similarly interact through feedback at the hypothalamus. Patients on fertility medications, hormonal cancer therapies, or contraceptives should coordinate all such use with their prescribing clinicians.
Safety Profile
Common Side Effects
Cautions
- • Active clinical research compound
- • Hormonal effects require monitoring
- • Not FDA-approved for therapeutic use
What We Don't Know
Optimal dosing, long-term effects, and clinical applications are still being established through ongoing research.
Legal Status
United States
Kisspeptin is not FDA-approved for any indication. Clinical trials continue (Imperial College collaboration, Myovant's MVT-602). Available through research-chemical suppliers; not a controlled substance. Not on FDA's 503A compounding bulk list. Fertility-clinic trial settings are the only legitimate human-use pathway currently.
International
Similarly investigational in the EU, UK, Canada, and Australia. The UK has hosted most of the human clinical research but kisspeptin has no marketing authorization from MHRA or EMA.
Sports & Competition
Not explicitly listed by WADA by name but falls under S2 (peptide hormones) and S4 (hormone and metabolic modulators) via catch-all language, since any peptide that stimulates LH/testosterone release would be prohibited at all times in competitive sport. Athletes must avoid.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Kisspeptin is a testosterone booster you can use like TRT.
Reality
Kisspeptin does acutely raise LH and testosterone — but tachyphylaxis with continuous or frequent dosing makes sustained testosterone elevation mechanistically difficult. Chronic TRT goals are better served by approved strategies (testosterone esters, clomiphene/enclomiphene for endogenous stimulation) under medical supervision. Kisspeptin's clinically useful applications are acute-trigger events (IVF) or targeted HPG-axis diagnostics, not chronic androgen support.
Myth
Kisspeptin works like PT-141 or Viagra for sexual desire.
Reality
Kisspeptin's effect on sexual desire brain processing is real — Dhillo's HSDD trials in both men and women showed enhanced sexual brain responses to erotic stimuli. But the mechanism is fundamentally different from PT-141 (central melanocortin) or PDE5 inhibitors (peripheral vascular). Whether kisspeptin becomes a clinically useful sexual desire intervention requires more research; it is not currently prescribable for that purpose, and the research-chemical supply for self-use bypasses the dosing and safety framework that made Dhillo's work rigorous.
Myth
Kisspeptin will replace hCG for IVF because it's safer.
Reality
Kisspeptin-54 genuinely does reduce OHSS risk in head-to-head IVF trigger trials — Dhillo's group has shown this in multiple RCTs. But regulatory approval has not followed the clinical signal, and hCG remains the global standard. Kisspeptin-54 is not yet commercially available for IVF use outside research trials, and widespread clinical adoption depends on regulatory and commercial decisions that have not yet been made.
Myth
Research-chemical kisspeptin is equivalent to the trial-validated peptide.
Reality
Clinical trials use carefully characterized peptide sourced under GMP conditions with certificate-of-analysis purity and correct sequence verification. Research-chemical kisspeptin — particularly the kisspeptin-10 fragment sold by gray-market suppliers — has unknown purity, potentially incorrect sequence, and no sterility assurance. For a compound that directly manipulates the reproductive hormonal axis, this matters substantially more than for most research chemicals. The dosing protocols in published clinical trials cannot be assumed to translate to unverified supply.
Myth
Kisspeptin is a natural hormone so it's inherently safe.
Reality
Endogenous kisspeptin is tightly pulsatile and context-dependent — acting at precisely coordinated moments in reproductive physiology. Exogenous administration delivers kisspeptin in ways and at doses that do not replicate normal physiology. Safety in supervised clinical trials does not imply safety in unsupervised self-administration, especially given the reproductive-axis effects and the unverified supply quality from research-chemical sources. 'Natural peptide' is a category, not a safety assurance.
Published Research
49 studiesSex Differences in Leptin Levels in Children and Adolescents with Normal Weight and Overweight/Obesity Across Pubertal Stages: A Systematic Review and Meta-analysis
Associations between kisspeptin hormone level and its genetic polymorphisms with polycystic ovary syndrome
Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans
Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety in Humans
Effect of a GnRH injection on kisspeptin levels in girls with suspected precocious puberty: a randomized-controlled pilot study
Role of serum kisspeptin as a biomarker to detect miscarriage: a systematic review and meta-analysis
An association between fat mass and obesity-associated (FTO) (rs9939609) and kisspeptin-1 (KISS-1) (rs4889, rs372790354) gene polymorphisms with polycystic ovary syndrome: an updated meta-analysis and power analysis
Kisspeptin expression levels in patients with placenta previa: A randomized trial
Kisspeptin and its Current Clinical Status-A Systematic Review.
Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals
The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B.
Oral sodium oxybate does not alter plasma kisspeptin levels in healthy male volunteers
Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
Kisspeptin in the Prediction of Pregnancy Complications.
The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction.
Green tea catechin EGCG could prevent obesity-related precocious puberty through NKB/NK3R signaling pathway
Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men
Diagnostic Value of Kisspeptin Levels on Early Pregnancy Outcome: a Systematic Review and Meta-analysis
Preeclampsia and gestational hypertension are associated to low maternal circulating kisspeptin levels: a systematic review and meta-analysis
Lower circulating kisspeptin and primary hypogonadism in men with type 2 diabetes.
Outcomes comparison of IVF/ICSI among different trigger methods for final oocyte maturation: A systematic review and meta-analysis
Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome
Kisspeptin Levels in Girls with Precocious Puberty: A Systematic Review and Meta-Analysis
Serum kisspeptin levels in polycystic ovary syndrome: A meta-analysis
Circulating kisspeptin and anti-müllerian hormone levels, and insulin resistance in women with polycystic ovary syndrome: A systematic review, meta-analysis, and meta-regression
Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women
The Effects of Kisspeptin on Brain Response to Food Images and Psychometric Parameters of Appetite in Healthy Men
Epigallocatechin gallate decreases plasma triglyceride, blood pressure, and serum kisspeptin in obese human subjects
Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome
Metabolic regulation of kisspeptin - the link between energy balance and reproduction.
Kisspeptin enhances brain responses to olfactory and visual cues of attraction in men
Kisspeptin and Glucose Homeostasis.
Kisspeptin as a Behavioral Hormone.
Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome.
The role of Kisspeptin levels in polycystic ovary syndrome: a systematic review and meta-analysis
Circulatory metastin/kisspeptin-1 in polycystic ovary syndrome: a systematic review and meta-analysis with diagnostic test accuracy
Modulations of human resting brain connectivity by kisspeptin enhance sexual and emotional functions
The effects of kisspeptin on β-cell function, serum metabolites and appetite in humans
Divergent responses to kisspeptin in children with delayed puberty.
A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.
Kisspeptin modulates sexual and emotional brain processing in humans.
Kisspeptin Responsiveness Signals Emergence of Reproductive Endocrine Activity: Implications for Human Puberty.
Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy.
Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.
Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea.
Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis.
Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women.
Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males.
Quick Facts
- Class
- Neuropeptide
- Tier
- C
- Evidence
- Moderate
- Safety
- Moderate Data
- Updated
- Mar 2026
- Citations
- 49PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.